Role of novel cancer gene SLITRK3 to activate NTRK3 in squamous cell lung cancer

The development of targeted therapies that inhibit cancer-driving oncogenes has improved outcomes of patients diagnosed with lung adenocarcinoma (LUAD). In contrast, patients diagnosed with lung squamous cell carcinoma (LUSC) suffer worse survival outcomes and lack effective targeted treatment optio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bollig-Fischer, Aliccia, Bao, Bin, Manning, Morenci, Dyson, Greg, Michelhaugh, Sharon K., Mittal, Sandeep, Bepler, Gerold, Mamdani, Hirva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607376/
https://www.ncbi.nlm.nih.gov/pubmed/35006496
http://dx.doi.org/10.1186/s43556-021-00051-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607376/
https://www.ncbi.nlm.nih.gov/pubmed/35006496
http://dx.doi.org/10.1186/s43556-021-00051-2

Ejemplares similares